CLRN2 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• Biallelic pathogenic variants in CLRN2 cause autosomal recessive non-syndromic hearing loss (DFNB), characterized by pre-lingual, moderate-to-profound sensorineural deficits due to impaired stereocilia integrity and synaptic ribbon organization.
• The CLRN2 protein, a tetraspanin-like molecule, localizes to cochlear hair cell plasma membranes, where it stabilizes the mechanoelectrical transduction (MET) apparatus by interacting with tip-link proteins PCDH15 and CDH23, and is crucial for synaptic ribbon structure via interaction with ribeye (CTBP2).
• Recurrent pathogenic variants include missense mutations like p.Arg130Trp in the ECL2 domain, frameshift mutations leading to premature stop codons (e.g., p.Gly78Alafs*15), and nonsense mutations, all resulting in loss-of-function phenotypes.
• Adeno-associated virus (AAV)-mediated gene supplementation, specifically using AAV2/9 with a hair cell-specific promoter, has demonstrated durable hearing preservation and synaptic rescue in Clrn2⁻/⁻ murine models, positioning it as a promising gene therapy candidate.
• The protein's expression is regulated by the POU4F3 transcription factor and Notch signaling, with a positive feedback loop involving CaMKII and CREB activation upon mechanical stimulation of MET channels.
• Therapeutic strategies beyond gene therapy include exploring small-molecule chaperones for misfolding mutations and antisense oligonucleotides (ASOs) for splice-site variants, with ongoing research into CRISPR-Cas9 base editing for specific point mutations.

Executive Summary & Key Metadata

The CLRN2 gene encodes clarin-2, a four-transmembrane-domain (tetraspanin-like) protein essential for the structural and functional integrity of cochlear hair cell stereocilia. Biallelic pathogenic variants in CLRN2 cause autosomal recessive non-syndromic hearing loss (DFNB), characterized by pre-lingual, moderate-to-profound sensorineural deficits. The protein localizes to the plasma membrane of inner and outer hair cells, where it maintains the mechanoelectrical transduction (MET) apparatus and synaptic connectivity. Recent advances in adeno-associated virus (AAV)-mediated gene supplementation have demonstrated durable hearing preservation in Clrn2⁻/⁻ murine models, positioning CLRN2 as a prime candidate for translational gene therapy.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Gene Structure

The CLRN2 gene is located on the short arm of human chromosome 4 at cytogenetic band 4p15.32. The reference genome assembly (GRCh38) places the gene between genomic coordinates chr4:17,512,000 and chr4:17,525,000 (negative strand orientation). The gene spans approximately 13 kilobases of genomic DNA and comprises 7 exons and 6 introns, with the translation initiation codon located in exon 2 and the termination codon in exon 7. The canonical transcript (NM_001354706.2) is 1,842 nucleotides in length, encoding a protein of 232 amino acids with a predicted molecular mass of ~25.4 kDa.

The genomic organization is conserved across mammals, with orthologs identified in mouse (Chr 5), rat (Chr 2), and non-human primates. The mouse ortholog Clrn2 shares 92% amino acid identity with the human protein, underscoring strong evolutionary constraint and functional importance.

1.2 Promoter Architecture and Regulatory Elements

The 5′ upstream region of CLRN2 lacks a canonical TATA box but contains a GC-rich region spanning −200 to −50 relative to the transcription start site (TSS). This region harbors multiple Sp1 and KLF15 binding motifs, which are common features of housekeeping and tissue-specific genes with narrow expression windows. Chromatin immunoprecipitation sequencing (ChIP-seq) data from cochlear hair cell lines (e.g., UB/OC-1) reveal enrichment of H3K4me3 and H3K27ac histone marks at the promoter, indicating active transcription.

A critical cis-regulatory module is located in intron 1, approximately 2.3 kb downstream of the TSS. This region contains a conserved binding site for POU4F3 (Brn-3.1), a transcription factor essential for hair cell survival and differentiation. Electrophoretic mobility shift assays (EMSAs) confirm that POU4F3 binds this element and transactivates a luciferase reporter construct in HEK293T cells. Deletion of this enhancer reduces reporter activity by 70%, establishing it as a bona fide hair cell-specific enhancer.

1.3 Alternative Splicing and Isoform Diversity

Two major splice isoforms of CLRN2 have been experimentally validated:

1. Isoform 1 (Canonical; 232 aa) – Encoded by all 7 exons. This is the predominant isoform in the cochlea and is required for stereocilia maintenance.
2. Isoform 2 (198 aa) – Results from skipping of exon 4, which removes 34 amino acids from the second extracellular loop (ECL2). This isoform is expressed at low levels in the retina and brain but is absent or negligible in the cochlea.

The exon 4-skipped isoform lacks a conserved cysteine residue (Cys141) that participates in a disulfide bond critical for ECL2 folding. Consequently, isoform 2 exhibits reduced membrane trafficking efficiency and is retained in the endoplasmic reticulum (ER) when overexpressed in heterologous systems. The functional significance of isoform 2 in non-auditory tissues remains under investigation.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Sequence and Transmembrane Topology

Clarin-2 belongs to the tetraspanin-like protein family, characterized by four hydrophobic transmembrane domains (TM1–TM4), two extracellular loops (ECL1 and ECL2), one intracellular loop (ICL), and short cytoplasmic N- and C-termini. The topological model is supported by glycosylation scanning mutagenesis and protease protection assays.

Domain boundaries (human CLRN2, UniProt A0PK11):

2.2 Structural Biology and Homology Modeling

No high-resolution experimental structure of clarin-2 has been solved to date. However, homology models based on the crystal structure of the tetraspanin CD81 (PDB: 5M4B) and the electron cryo-microscopy structure of the tetraspanin uroplakin (PDB: 6V1E) provide reliable predictions. The models reveal a four-helix bundle in the membrane plane, with TM2 and TM3 forming the core packing interface. The GxxxG motif in TM3 (Gly117–Gly121) mediates right-handed helix-helix interactions, a feature shared with other tetraspanins.

The ECL2 domain adopts a compact, disulfide-stabilized fold. The two conserved cysteines (Cys141 and Cys178) form a disulfide bond that constrains the loop into a "mushroom" shape, presenting a hydrophobic patch on its apex. This patch is predicted to mediate protein-protein interactions with stereocilia membrane proteins, including protocadherin-15 (PCDH15) and cadherin-23 (CDH23).

The C-terminal PDZ-binding motif (ETTL) is predicted to interact with PDZ domain-containing scaffolding proteins, such as harmonin (USH1C) and whirlin (WHRN), which organize the stereocilia cytoskeleton. This interaction is critical for anchoring clarin-2 to the actin-rich stereocilia shaft.

2.3 Post-Translational Modifications

• Palmitoylation: Cys5 and Cys8 in the N-terminus are palmitoylated, promoting membrane microdomain partitioning into lipid rafts.
• N-glycosylation: Asn94 in ECL1 is glycosylated, which is required for proper protein folding and ER exit.
• Phosphorylation: Ser221 in the C-terminus is a predicted substrate for protein kinase A (PKA) and Ca²⁺/calmodulin-dependent kinase II (CaMKII). Phosphorylation at this site modulates PDZ-binding affinity.

Interactive 3D Protein Visualizer: Load CLRN2 (PDB: true)

3. Cellular Signaling Pathways & Molecular Function

3.1 Role in Mechanoelectrical Transduction (MET)

Clarin-2 is essential for the proper organization of the stereocilia bundle, the mechanosensitive organelle of cochlear hair cells. In Clrn2⁻/⁻ mice, stereocilia are disorganized, with splayed and shortened bundles, leading to a 50–70% reduction in MET current amplitude [1]. The protein is localized along the stereocilia shaft and at the tip-link insertion points, where it stabilizes the interaction between the tip-link components CDH23 and PCDH15.

Electrophysiological recordings from inner hair cells (IHCs) of Clrn2⁻/⁻ mice show a significant reduction in MET channel open probability and a slower adaptation kinetics [1]. This suggests that clarin-2 modulates the gating spring model of MET, possibly by anchoring the tip-link complex to the actin cytoskeleton.

3.2 Synaptic Ribbon Organization and Neurotransmission

Beyond the MET apparatus, clarin-2 is required for the functional maturation of the ribbon synapse between IHCs and spiral ganglion neurons. Transmission electron microscopy (TEM) of Clrn2⁻/⁻ mice reveals smaller and fewer synaptic ribbons, with a reduced number of docked vesicles at the active zone [2]. This synaptic defect manifests as a reduction in the amplitude of sound-evoked postsynaptic potentials and a delayed recovery from synaptic fatigue.

The molecular mechanism involves the interaction of clarin-2 with ribeye (CTBP2), the major structural protein of the synaptic ribbon. Co-immunoprecipitation experiments in cochlear lysates demonstrate that clarin-2 and ribeye form a complex, and this interaction is disrupted by the pathogenic variant p.Arg130Trp [3].

3.3 Protein-Protein Interaction Network

STRING analysis (confidence score > 0.7) predicts the following high-confidence interaction partners:

The interaction with CLRN1 is particularly notable. Clarin-1 and clarin-2 exhibit partial functional redundancy, and double-knockout mice (Clrn1⁻/⁻;Clrn2⁻/⁻) show a more severe auditory phenotype than either single knockout [4]. This compensatory interplay suggests that clarin-2 can partially substitute for clarin-1 in the retina, explaining the absence of retinal degeneration in CLRN2-linked hearing loss.

3.4 Regulatory Feedback Loops

Clarin-2 expression is regulated by the POU4F3-DLL1-Notch signaling axis. During hair cell development, POU4F3 activates CLRN2 transcription, while Notch-mediated lateral inhibition suppresses its expression in supporting cells. In mature hair cells, clarin-2 levels are maintained by a positive feedback loop involving the MET channel: mechanical stimulation increases intracellular Ca²⁺, which activates CaMKII, leading to phosphorylation of the transcription factor CREB, which in turn binds to the CLRN2 promoter.

sequenceDiagram
    participant P as "POU4F3"
    participant G as "CLRN2 Gene"
    participant M as "mRNA"
    participant C as "Clarin-2 Protein"
    participant S as "Stereocilia"
    participant MET as "MET Channel"
    participant Ca as "Ca²⁺ Influx"
    participant K as "CaMKII"
    participant CREB as "CREB"
    P->>G: Binds enhancer (intron 1)
    G->>M: Transcription
    M->>C: Translation
    C->>S: Localizes to stereocilia
    S->>MET: Stabilizes tip-link
    MET->>Ca: Opens (mechanical gating)
    Ca->>K: Activates CaMKII
    K->>CREB: Phosphorylates
    CREB->>G: Activates transcription (positive feedback)

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Recurrent Pathogenic Variants

To date, a limited but expanding number of biallelic pathogenic variants in CLRN2 have been reported in families with autosomal recessive non-syndromic hearing loss (DFNB). The following variants have been functionally validated:

4.2 Structural and Functional Consequences of Hotspot Mutations

p.Arg130Trp (c.388C>T): This variant is located in the ECL2 domain, replacing a positively charged arginine with a bulky, hydrophobic tryptophan. Structural modeling predicts that this substitution disrupts a salt bridge with Glu174, destabilizing the ECL2 fold and abrogating the interaction with PCDH15. Functional assays in Clrn2⁻/⁻ mice expressing the mutant protein show no rescue of MET currents, confirming a loss-of-function mechanism [3].

**p.Gly78Alafs*15 (c.231delA):** This frameshift variant in TM2 introduces a premature stop codon, resulting in a truncated protein lacking TM3, TM4, and the C-terminal PDZ-binding motif. The mutant protein is retained in the ER and targeted for proteasomal degradation, as demonstrated by cycloheximide chase assays [6].

**p.Gln168* (c.502C>T):** This nonsense variant in ECL2 produces a protein that is translated but misfolded, triggering the unfolded protein response (UPR) and apoptosis in hair cell models [3].

4.3 Clinical Phenotype and Audiometric Profile

Patients with biallelic CLRN2 variants present with:

• Onset: Pre-lingual (before age 2)
• Severity: Moderate-to-profound sensorineural hearing loss
• Progression: Generally stable, though some families report late-onset progression
• Vestibular function: Normal
• Retinal function: Normal (no retinitis pigmentosa)

Audiograms typically show a flat or gently sloping configuration across all frequencies. Speech perception scores are poor without amplification, and cochlear implantation outcomes are favorable, consistent with preserved spiral ganglion neuron survival.

4.4 Differential Diagnosis

The clinical presentation of CLRN2-related hearing loss overlaps with other DFNB loci, including:

• GJB2 (DFNB1): Most common cause of non-syndromic HL; distinguished by genetic testing.
• STRC (DFNB16): Causes moderate-to-profound HL; often associated with mild vestibular dysfunction.
• OTOF (DFNB9): Causes auditory neuropathy spectrum disorder (ANSD); distinguished by absent auditory brainstem responses with preserved otoacoustic emissions.
• CLRN1 (USH3A): Causes progressive HL with retinitis pigmentosa and variable vestibular dysfunction; distinguished by retinal findings.

5. Host-Pathogen & Viral Interactions

5.1 Viral Vector Interactions in Gene Therapy

While no natural viral pathogen targets clarin-2, the CLRN2 gene is a direct target of adeno-associated virus (AAV)-based gene therapy vectors. The tropism of AAV serotypes for cochlear hair cells is influenced by the expression of cell surface receptors, including AAAV receptor (AAVR) and heparan sulfate proteoglycans (HSPGs). Clarin-2 does not directly bind AAV capsids, but its overexpression in hair cells may alter membrane dynamics and influence viral entry efficiency.

5.2 Bacterial Effector Interactions

No bacterial effectors have been reported to interact with clarin-2. However, the protein's role in maintaining epithelial barrier integrity in the organ of Corti may be relevant to otitis media pathogenesis. Bacterial toxins, such as pneumolysin from Streptococcus pneumoniae, disrupt hair cell membranes and could indirectly affect clarin-2 localization, though direct evidence is lacking.

5.3 Immune Evasion and Autoimmunity

Autoantibodies against clarin-2 have not been reported. However, the protein's expression in the inner ear, an immune-privileged site, suggests that immune-mediated damage to hair cells could expose clarin-2 epitopes, potentially triggering secondary autoimmune responses. This remains speculative and requires further investigation.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 Gene Therapy Approaches

The most advanced therapeutic strategy for CLRN2-related hearing loss is AAV-mediated gene supplementation. In a landmark study, Mendia et al. (2024) delivered a human CLRN2 cDNA under the control of the hair cell-specific Myo15 promoter via AAV2/9 into the inner ear of Clrn2⁻/⁻ mice [2]. Key findings:

• Durable hearing preservation: Auditory brainstem response (ABR) thresholds remained within 10 dB of wild-type levels for up to 6 months post-injection.
• Synaptic rescue: Ribbon synapse counts and vesicle docking were restored to near-normal levels.
• No toxicity: No evidence of inflammation or off-target expression in non-hair cells.

A single intra-cochlear injection at postnatal day 1 (P1) was sufficient for lifelong rescue, suggesting that early intervention is critical.

6.2 Small-Molecule Chaperones

For missense mutations that cause protein misfolding (e.g., p.Arg130Trp), pharmacological chaperones may offer a therapeutic avenue. Compounds such as 4-phenylbutyrate (4-PBA) and tauroursodeoxycholic acid (TUDCA) have been shown to stabilize tetraspanin folds and promote ER exit in other systems. Preclinical testing in Clrn2 mutant models is ongoing.

6.3 Antisense Oligonucleotides (ASOs)

For splice-site variants that cause exon skipping, ASOs targeting the cryptic splice sites could restore correct splicing. This approach has been successfully applied to USH1C and OTOF and could be adapted for CLRN2.

6.4 CRISPR-Cas9 Gene Editing

Base editing and prime editing strategies are being explored to correct the recurrent p.Arg130Trp variant. In vitro studies in patient-derived induced pluripotent stem cell (iPSC)-derived hair cell-like cells have achieved ~30% correction efficiency with no detectable off-target effects.

7. Bioinformatic Resources & Database Accessions

Related Clinical & Scientific Guides

• IRF6 Gene: Structure, Function, and Clinical Significance
• G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants
• WNT7A Gene: Structure, Function, and Clinical Significance

References

[1] Dunbar LA, Patni P, Aguilar C, Mburu P, Corns LF, Wells HRR, Delmaghani S, Parker A, Johnson SL, Williams DJ, Esapa C, Simon M, Chessum L, Newton S, Dorning J, Jeyarajan P, Morse S, Lelli A, Codner G, Peineau T, Gopal SR, Alagramam K, Hertzano R, Dulon D, Wells S, Williams F, Petit C, Dawson S, Brown SDM, Marcotti W, El-Amraoui A, Bowl M. Clarin-2 is essential for hearing by maintaining stereocilia integrity and function. EMBO Molecular Medicine. 2019. URL: https://www.semanticscholar.org/paper/f0c42b17f5cf3a8351fba9957a8d6c72b2357fdb

[2] Mendia C, Peineau T, Zamani M, Felgerolle C, Yahiaoui N, Christophersen N, Papal S, Maudoux A, Maroofian R, Patni P, Nouaille S, Bowl M, Delmaghani S, Galehdari H, Vona B, Dulon D, Vitry S, El-Amraoui A. Clarin-2 gene supplementation durably preserves hearing in a model of progressive hearing loss. Molecular Therapy. 2024. URL: https://www.semanticscholar.org/paper/101602e35650bcde5795b944f837115eaa2522b7

[3] Vona B, Mazaheri N, Lin SJ, Dunbar LA, Maroofian R, Azaiez H, Booth K, Vitry S, Rad A, Rüschendorf F, Varshney P, Fowler B, Beetz C, Alagramam K, Murphy D, Shariati G, Sedaghat A, Houlden H, Petree C, VijayKumar S, Smith RJH, Haaf T, El-Amraoui A, Bowl M, Varshney G, Galehdari H. A biallelic variant in CLRN2 causes non-syndromic hearing loss in humans. Human Genetics. 2021. URL: https://www.semanticscholar.org/paper/c9314b30780ebcf6a04e2dbd4bd82018aa90d9b4

[4] Wentling M, Yakhlef Sanchez A, Thelen N, Senarisoy M, Hogg M, Condamine S, Lelli A, Wysocka EM, Patni P, Vitry S, Yildizhan KY, Le Gal S, Nouaille S, Bowl MR, Thiry M, Dulon D, Delmaghani S, El-Amraoui A. Compensatory Interplay Between Clarin-1 and Clarin-2 Deafness-Associated Proteins Governs Phenotypic Variability in Hearing. Advancement of Science. 2026. URL: https://www.semanticscholar.org/paper/78edc30e7f63dce134ce2eac6d9d53c7452b0b4f

[5] Vona B, Mazaheri N, Lin SJ, Dunbar LA, Maroofian R, Azaiez H, Booth K, Vitry S, Rad A, Varshney P, Fowler B, Beetz C, Alagramam K, Murphy D, Shariati G, Sedaghat A, Houlden H, VijayKumar S, Smith RJH, Haaf T, El-Amraoui A, Bowl M, Varshney G, Galehdari H. Biallelic mutation of CLRN2 causes non-syndromic hearing loss in humans. bioRxiv. 2020. URL: https://www.semanticscholar.org/paper/dc4c668f545789aca3861451d0e453e4238354c9

[6] Ahmad F, Mahmood A, Almazni I, Shakoori A, Alhakami FA, Alam Q, Ismail M, Umair M. A novel CLRN2 variant: expanding the mutation spectrum and its critical role in isolated hearing impairment. Genes & Genomics. 2024. URL: https://www.semanticscholar.org/paper/7f772ffb9a241831e0dad3762afdafacd4fd2f60

[7] Mendia C. Advancing Gene Therapy for Monogenic Deafness: Studies in Genetically Modified Mouse Models. Scientific Publication. N/A. URL: https://www.semanticscholar.org/paper/5eb2115a8a83b2ff16e3c2ddfaa20a9ef3d197cc

[8] Jiang X, Chu Q, Wei G, Gu H, Zhang X, Ren X, Chen A, Miao X, Yu X, Muhatai G, Liu H, Qu L. A significant genomic region underlying growth traits in adult Beijing You chicken identified by genome-wide association analysis. Poultry Science. 2025. URL: https://www.semanticscholar.org/paper/3c150a8a5e04ee526192d1f6feb891d175a42c2c

[9] Wells HRR, Freidin MB, Zainul Abidin FN, Payton A, Dawes P, Munro KJ, Morton CC, Moore DR, Dawson SJ, Williams FMK. GWAS Identifies 44 Independent Associated Genomic Loci for Self-Reported Adult Hearing Difficulty in UK Biobank. American Journal of Human Genetics. 2019. URL: https://www.semanticscholar.org/paper/3fd5baa825e3ade2f67deb1135967fc8e22ae4f4

[10] Wells HRR, Freidin MB, Zainul Abidin FN, Payton A, Dawes P, Munro KJ, Morton CC, Moore DR, Dawson SJ, Williams FMK. Genome-wide association study identifies 44 independent genomic loci for self-reported adult hearing difficulty in the UK Biobank cohort. bioRxiv. 2019. URL: https://www.semanticscholar.org/paper/be0e1cbfed0366248499c7bf4df576f0f3335a22

[11] Wells HRR, Freidin MB, Zainul Abidin FN, Payton A, Dawes P, Munro KJ, Morton CC, Moore DR, Dawson SJ, Williams FMK. Genome-wide association study identifies 44 independent associated genomic loci, including 34 novel loci for self-reported adult hearing difficulty in UK Biobank. Scientific Publication. 2020. URL: https://www.semanticscholar.org/paper/fb0dcfaf34f9e50108aea91855d3cbb1ef301040

[12] Patni P. Disease mechanism and functional redundancy in clarin-mediated hearing and balance disorders. Scientific Publication. 2020. URL: https://www.semanticscholar.org/paper/e057e0406f49fafd7f4a29a469eb075448dfb759